Health resource utilization and clinical outcomes with risperidone therapy in patients with serious mental illness

Comprehensive Psychiatry

Volumn 40, Issue 3, 1999, Pages 198-202

  Sajatovic, Martha ^a   Ramirez, Luis F ^b   Belton, Joan ^b   McCormick, Richard ^b  

^a ODMH Northcoast Behavioral Healthcare   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INFORMATION SYSTEM; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL DISEASE; OUTCOMES RESEARCH; OUTPATIENT CARE; PSYCHOSIS;

EID: 0032962256     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-440X(99)90003-2     Document Type: Article

References (28)

1. Peralta V, Cuesta MJ, De Leon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biol Psychiatry 1995;35:726-736.
2. Carpenter ST Jr, Buchanan RW. Schizophrenia. N Engl J Med 1994;330:680-690.
3. Attkisson C, Cook J, Karno M, Lehman A, McGlashan TH, Meltzer HY, et al. Clinical services research. Schizophr Bull 1992;18:561-626.
4. Lehman AF. Evaluating outcomes of treatment for persons with psychotic disorders. J Clin Psychiatry 1996;57:61-67.
5. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154:4.
6. Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. J Clin Psychiatry 1996;57:49-56.
7. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, et al. Cost-effectiveness of clozapine in treatment-resistant patients. Am J Psychiatry 1993;150:1630-1638.
8. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-926.
9. Albright PS, Livingston S, Keegan DL, Ingham M, Shrikhande S, LeLorier J. Reduction of healthcare resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable data bases. Clin Drug Invest 1996;5:289-299.
10. Lindstrom E, Van Knorring L, Eberhard G. Studies of selected outcome-related clinical parameters following short-term and long-term treatment with risperidone: a retrospective setting. The Annual Meeting of the International College of Neuropsychopharmacology; 1994 June 27-July 1; Washington, DC.
11. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996;57:66-76.
12. Chouinard G, Albright P. Economic and health utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997;17:298-307.
13. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41: 850-854.
14. Janicak PG, Davis JM, Preskorn SH, Ayd F. Principles and Practice of Psychopharmacology. Baltimore, MD: Williams & Wilkins, 1993:93-184.
15. Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
16. Fischer-Cornelssen KA, Ferner UJ. An example of European multicentre trials: multispectral analysis of clozapine. Psychopharmacol Bull 1992;12:34-39.
17. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
18. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
19. Bondalfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998;155:499-504.
20. Buckley PF, Donenwirth K, Bayer KE, Lys C, Ibrahim Z, Schulz SC. Risperidone for treatment resistant schizophrenia: initial clinical experience in a state hospital. J Pharm Technol 1996;12:271-275.
21. Marder S. Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry 1996;57:26-30.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Ed. 4. Washington, DC: American Psychiatric Association, 1994.
23. McElroy S, Keck P, Pope H. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987;7: 16-24.
24. Frankenburg F, Kalunian D. Clozapine in the elderly. J Geriatr Psychiatry Neurol 1994;7:129-132.
25. Sajatovic M, Ramirez L, Vernon L, Brescan D, Simon M, Jurjus G. Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry Med 1996;26:309-317.
26. Department of Veterans Affairs. Annual Report of the Secretary of Veterans Affairs. Fiscal Year, 1994. US Department of Veterans Affairs, 1995.
27. Sajatovic M, Vernon L, Semple W. Gender specific clinical and health resource utilization differences in veterans with serious mental illness. Psychiatr Serv 1997;48:1461-1463.
28. Müller-Spahn F, The International Risperidone Research Group. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992;15(1 Suppl): 90A.